Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tyrosine-protein phosphatase non-receptor type 18 (PTPN18)
- Target
- PTPN18
- Molecular classification
- Enzyme, Non-receptor protein tyrosine phosphatase, Intracellular (non-membrane spanning) phosphatase
01
Overview
Tyrosine-protein phosphatase non-receptor type 18 (PTPN18) is an intracellular enzyme of the protein tyrosine phosphatase family, encoded by the PTPN18 gene. It acts by dephosphorylating tyrosine residues on target proteins, which regulates key cellular processes including growth, differentiation, cell cycle, and signal transduction. PTPN18 contains a PEST motif implicated in protein-protein interactions and intracellular stability. Its subcellular localization (nuclear vs. cytoplasmic) appears to determine its function as a tumor suppressor (notably in breast and hepatocellular cancer) or as a potential promoter of malignancy (notably in colorectal and endometrial cancer). It has been shown to regulate autophosphorylated tyrosine kinases such as HER2, but its detailed substrates and functions are still under investigation. Currently, there are no specific approved drugs or established clinical biomarkers associated directly with PTPN18
- Other names
- PTPN18PTP-HSCFBDP1
02
Mechanism of action
Dephosphorylation of tyrosine-phosphorylated substrates, including regulation of autophosphorylated tyrosine kinases such as HER2 May act as a tumor suppressor or oncogene by modulating specific kinase pathways, depending on subcellular localization and cancer type
03
Biological functions
Signal transductionRegulation of cell growthRegulation of cell differentiationCell cycle/mitosis regulationModulation of oncogenic transformationProtein dephosphorylation
04
Disease associations
Cancer (implicated as both tumor suppressor and promoter, depending on context, especially in breast, colorectal, hepatocellular, and endometrial cancers)Other (potential additional associations, but cancer is the primary disease link currently recognized)
05
Safety considerations
Notable challenges include the dual and context-dependent roles in cancer biology (acting as tumor suppressor in some tissues, oncogenic in others), complicating therapeutic development or biomarker useOff-target effects and specificity are broader challenges for the protein tyrosine phosphatase family
06
Interacting drugs
There are currently no widely recognized small molecules or clinically approved drugs specifically reported to target PTPN18 in humans. Some general tyrosine phosphatase inhibitors exist (research tools), but not PTPN18-specific.
07
Biomarkers
No established biomarkers for patient selection or monitoring in clinical practice currently identified for PTPN18
Beyond the preview
Go deeper on Tyrosine-protein phosphatase non-receptor type 18 (PTPN18).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tyrosine-protein phosphatase non-receptor type 18 (PTPN18).